# Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor

> **NCT02261207** · PHASE2 · COMPLETED · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 17 (actual)

## Conditions studied

- Solitary Fibrous Tumor

## Interventions

- **DRUG:** Axitinib

## Key facts

- **NCT ID:** NCT02261207
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2017-10
- **Final completion:** 2018-03
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2021-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02261207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02261207, "Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02261207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*